$ALDX
Aldeyra Therapeutics, Inc.

2017 Q1 Form 10-K Financial Statement

#000119312517104228 Filed on March 30, 2017

View on sec.gov

Income Statement

Concept 2017 Q1 2016 Q2 2016
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.730M $1.460M $5.520M
YoY Change 18.49% 53.68% 25.17%
% of Gross Profit
Research & Development $3.369M $2.835M $13.18M
YoY Change -4.06% 126.93% 73.95%
% of Gross Profit
Depreciation & Amortization $9.660K $10.00K $35.79K
YoY Change 19.23% 90.61%
% of Gross Profit
Operating Expenses $3.369M $2.835M $13.18M
YoY Change -4.06% 126.93% 73.95%
Operating Profit -$5.096M -$4.297M -$18.70M
YoY Change 2.59% 94.95% 55.94%
Interest Expense $26.84K $27.82K $105.5K
YoY Change 7.2% -1.39% -6.05%
% of Operating Profit
Other Income/Expense, Net $4.780K -$5.866K -$3.472K
YoY Change -1612.66% -79.21% -96.57%
Pretax Income -$5.090M -$4.310M -$18.70M
YoY Change 2.41% 93.27% 54.67%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$5.091M -$4.303M -$18.70M
YoY Change 2.49% 92.75% 54.67%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$368.8K -$311.6K -$1.648M
COMMON SHARES
Basic Shares Outstanding 15.13M shares 9.713M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q1 2016 Q2 2016
SHORT-TERM ASSETS
Cash & Short-Term Investments $31.20M $32.50M $24.91M
YoY Change 35.65% -3.27% -9.71%
Cash & Equivalents $12.02M $17.61M $12.02M
Short-Term Investments $11.90M $14.90M $12.90M
Other Short-Term Assets $300.0K $300.0K $220.0K
YoY Change 0.0% 0.0% -56.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $31.47M $32.81M $25.13M
YoY Change 35.02% -3.04% -10.54%
LONG-TERM ASSETS
Property, Plant & Equipment $58.28K $75.03K $60.00K
YoY Change -28.46% 83.58% -25.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $0.00
YoY Change -100.0%
Total Long-Term Assets $58.28K $75.03K $60.00K
YoY Change -54.27% 83.58% -45.45%
TOTAL ASSETS
Total Short-Term Assets $31.47M $32.81M $25.13M
Total Long-Term Assets $58.28K $75.03K $60.00K
Total Assets $31.53M $32.88M $25.19M
YoY Change 34.54% -2.93% -10.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $694.9K $823.3K $280.0K
YoY Change 20.23% 30.82% -67.06%
Accrued Expenses $1.520M $1.085M $1.950M
YoY Change 46.77% 140.14% 63.87%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $193.9K $310.2K $80.00K
YoY Change 0.0% 0.0% 0.0%
Total Short-Term Liabilities $2.409M $2.373M $2.300M
YoY Change 33.26% 70.59% 8.49%
LONG-TERM LIABILITIES
Long-Term Debt $1.128M $992.6K $1.240M
YoY Change 2.32% 3.23% 2.48%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $1.128M $992.6K $1.240M
YoY Change 2.32% 3.23% 2.48%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.409M $2.373M $2.300M
Total Long-Term Liabilities $1.128M $992.6K $1.240M
Total Liabilities $3.537M $3.366M $3.540M
YoY Change 21.54% 43.06% 6.31%
SHAREHOLDERS EQUITY
Retained Earnings -$82.39M -$67.87M
YoY Change 29.61% 33.4%
Common Stock $110.4M $97.38M
YoY Change 31.27% 18.18%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $28.00M $29.52M $21.65M
YoY Change
Total Liabilities & Shareholders Equity $31.53M $32.88M $25.19M
YoY Change 34.54% -2.93% -10.67%

Cashflow Statement

Concept 2017 Q1 2016 Q2 2016
OPERATING ACTIVITIES
Net Income -$5.091M -$4.303M -$18.70M
YoY Change 2.49% 92.75% 54.67%
Depreciation, Depletion And Amortization $9.660K $10.00K $35.79K
YoY Change 19.23% 90.61%
Cash From Operating Activities -$4.190M -$3.250M -$15.15M
YoY Change -6.47% 101.86% 62.73%
INVESTING ACTIVITIES
Capital Expenditures $11.59K $0.00 $11.81K
YoY Change 25.54% -100.0% -86.29%
Acquisitions
YoY Change
Other Investing Activities $900.0K -$2.100M -$210.0K
YoY Change -98.38%
Cash From Investing Activities $890.0K -$2.100M -$230.0K
YoY Change -9000.0% 6900.0% -98.24%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $10.58M $12.60M $12.65M
YoY Change -55.62%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 10.58M 12.81M 12.74M
YoY Change -105900.0% -34.24% -55.25%
NET CHANGE
Cash From Operating Activities -4.190M -3.250M -15.15M
Cash From Investing Activities 890.0K -2.100M -230.0K
Cash From Financing Activities 10.58M 12.81M 12.74M
Net Change In Cash 7.280M 7.460M -2.640M
YoY Change -261.78% -58.18% -143.14%
FREE CASH FLOW
Cash From Operating Activities -$4.190M -$3.250M -$15.15M
Capital Expenditures $11.59K $0.00 $11.81K
Free Cash Flow -$4.202M -$3.250M -$15.16M
YoY Change -6.41% 105.7% 61.36%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
6284058
CY2013Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
178000
CY2012Q2 aldx Warrant Liability
WarrantLiability
88000
CY2016Q1 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
67000
CY2017Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
15131880 shares
CY2016Q2 dei Entity Public Float
EntityPublicFloat
59217833
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
205000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8527304
CY2015Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
9.50
CY2015Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
1100000 shares
CY2015Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
7.00
CY2015Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
9.50
CY2015Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
1100000 shares
CY2015Q1 us-gaap Share Price
SharePrice
20.00
CY2015Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
7.00
CY2015Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
9.50
CY2015Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
211528 shares
CY2015Q1 us-gaap Share Price
SharePrice
20.00
CY2015Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
9.33
CY2015Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
9.50
CY2015Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
211528 shares
CY2015Q1 us-gaap Share Price
SharePrice
20.00
CY2015Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
9.33
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
413172
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
25927662
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
10115458
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2152854
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9712521 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9712521 shares
CY2015Q4 us-gaap Assets
Assets
28204764
CY2015Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
42021
CY2015Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2015Q4 us-gaap Assets Current
AssetsCurrent
28088194
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
14418095
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
83478851
CY2015Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
667688
CY2015Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
12941776
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14648866
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
591843
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
9713
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
851160
CY2015Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
42021
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-8361
CY2015Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
14460116
CY2015Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
932060
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1186429
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000 shares
CY2015Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1211310
CY2015Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
0
CY2015Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
77546
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q4 us-gaap Liabilities
Liabilities
3326445
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
28204764
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2115135
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
80334
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
24878319
CY2015Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
213
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.98
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-58601884
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
497552
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1077330 shares
CY2015Q4 aldx Deferred Tax Liabilities Note Discounts
DeferredTaxLiabilitiesNoteDiscounts
42021
CY2015Q4 aldx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
574742
CY2015Q4 aldx Accrued General And Administrative Expense Current
AccruedGeneralAndAdministrativeExpenseCurrent
198515
CY2015Q4 aldx Deferred Offering Costs Noncurrent
DeferredOfferingCostsNoncurrent
36236
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
983449
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
24517796
CY2016Q4 us-gaap Cash
Cash
394849
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
16669295
CY2016Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
24900000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2399666
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12576325 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12576325 shares
CY2016Q4 us-gaap Assets
Assets
25187679
CY2016Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
31292
CY2016Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2016Q4 us-gaap Assets Current
AssetsCurrent
25131327
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
21786477
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
98938446
CY2016Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1271891
CY2016Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
12897584
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12015061
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
772841
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
12576
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
275441
CY2016Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
31292
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
129
CY2016Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
24447455
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
21817769
CY2016Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
700215
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1946251
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000 shares
CY2016Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1238624
CY2016Q4 us-gaap Long Term Debt
LongTermDebt
1395833
CY2016Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
387731
CY2016Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
0
CY2016Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
77546
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
107195
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q4 us-gaap Liabilities
Liabilities
3537862
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
25187679
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2299238
CY2016Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
465278
CY2016Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
70212
CY2016Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
465278
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2185696
CY2016Q4 us-gaap Share Price
SharePrice
5.35
CY2016Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
77546
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
56352
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.34
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
21649817
CY2016Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
3861
CY2016Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
3200000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.63
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
802532 shares
CY2016Q4 us-gaap Securities For Reverse Repurchase Agreements
SecuritiesForReverseRepurchaseAgreements
11550000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-77301334
CY2016Q4 us-gaap Us Government Securities At Carrying Value
USGovernmentSecuritiesAtCarryingValue
12897455
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
218682
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1874659
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1498585 shares
CY2016Q4 aldx Deferred Tax Liabilities Note Discounts
DeferredTaxLiabilitiesNoteDiscounts
31292
CY2016Q4 aldx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
913838
CY2016Q4 aldx Indemnification Obligations Claims Outstanding
IndemnificationObligationsClaimsOutstanding
0
CY2016Q4 aldx Accrued General And Administrative Expense Current
AccruedGeneralAndAdministrativeExpenseCurrent
48964
CY2016Q4 aldx Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercised Intrinsic Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedIntrinsicValue
463604
CY2016Q4 aldx Cash Reserve For Indemnities And Guarantees
CashReserveForIndemnitiesAndGuarantees
0
CY2015Q2 us-gaap Proceeds From Repurchase Of Equity
ProceedsFromRepurchaseOfEquity
19500000
CY2015Q2 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
2822500 shares
CY2015Q1 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
1100000 shares
CY2015Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
7100000
CY2015Q1 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
1100000 shares
CY2015Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
7100000
CY2015Q1 aldx Redemption Price Of Warrants
RedemptionPriceOfWarrants
0.001
CY2015Q1 aldx Expiration Of Warrant
ExpirationOfWarrant
P3Y
CY2015Q1 aldx Average Trading Volume Of Common Stock
AverageTradingVolumeOfCommonStock
50000 shares
CY2015Q1 invest Investment Warrants Exercise Price
InvestmentWarrantsExercisePrice
0.125
CY2015Q1 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
211528 shares
CY2015Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
1900000
CY2015Q1 aldx Redemption Price Of Warrants
RedemptionPriceOfWarrants
0.001
CY2015Q1 aldx Expiration Of Warrant
ExpirationOfWarrant
P3Y
CY2015Q1 aldx Average Trading Volume Of Common Stock
AverageTradingVolumeOfCommonStock
50000 shares
CY2015Q1 invest Investment Warrants Exercise Price
InvestmentWarrantsExercisePrice
0.125
CY2015Q1 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
211528 shares
CY2015Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
1900000
CY2015Q1 aldx Redemption Price Of Warrants
RedemptionPriceOfWarrants
0.001
CY2015Q1 aldx Expiration Of Warrant
ExpirationOfWarrant
P3Y
CY2015Q1 aldx Average Trading Volume Of Common Stock
AverageTradingVolumeOfCommonStock
50000 shares
CY2016Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
12600000
CY2016Q2 us-gaap Sale Of Stock Transaction Date
SaleOfStockTransactionDate
2016-06-30
CY2016Q1 aldx Lease Agreement Area Of Office Space
LeaseAgreementAreaOfOfficeSpace
3188 sqft
CY2014 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
5604
CY2014 us-gaap Lessee Leasing Arrangements Operating Leases Term Of Contract
LesseeLeasingArrangementsOperatingLeasesTermOfContract
P37M
CY2014 aldx Lease Agreement Area Of Office Space
LeaseAgreementAreaOfOfficeSpace
3700 sqft
CY2015 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Other
EffectiveIncomeTaxRateReconciliationTaxCreditsOther
0.0104 pure
CY2015 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
35829
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2461938 shares
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2187102
CY2015 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.0192 pure
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
6121562
CY2015 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.40
CY2015 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0522 pure
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2187102
CY2015 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.4010 pure
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4414709
CY2015 us-gaap Depreciation
Depreciation
18778
CY2015 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12098648
CY2015 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.3400 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.0000 pure
CY2015 us-gaap Interest Paid
InterestPaid
74299
CY2015 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-101180
CY2015 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
291943
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-12090287
CY2015 us-gaap Interest Expense
InterestExpense
112306
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-13036256
CY2015 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
509866
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
264984
CY2015 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-8361
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-11989107
CY2015 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
12950137
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
28469571
CY2015 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-8361
CY2015 us-gaap Investment Income Interest
InvestmentIncomeInterest
11126
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-9311753
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
86119
CY2015 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
28505807
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7574398
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.78
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
2187102
CY2015 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
8633897 shares
CY2015 aldx Proceeds From Issuance Of Common Stock And Options Exercised
ProceedsFromIssuanceOfCommonStockAndOptionsExercised
28505807
CY2015 aldx Deferred Offering Costs Paid By Cash
DeferredOfferingCostsPaidByCash
36236
CY2016 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-266106
CY2016 dei Entity Registrant Name
EntityRegistrantName
ALDEYRA THERAPEUTICS, INC.
CY2016 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Other
EffectiveIncomeTaxRateReconciliationTaxCreditsOther
0.0003 pure
CY2016 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
27314
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2910289 shares
CY2016 dei Document Type
DocumentType
10-K
CY2016 dei Entity Central Index Key
EntityCentralIndexKey
0001341235
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2759753
CY2016 dei Document Period End Date
DocumentPeriodEndDate
2016-12-31
CY2016 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.0284 pure
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2633805
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.65
CY2016 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0524 pure
CY2016 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2759753
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.3942 pure
CY2016 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
CY2016 dei Amendment Flag
AmendmentFlag
false
CY2016 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2016 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5520308
CY2016 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> <b><i>Concentration of Credit Risk</i></b> &#x2013; Financial instruments that potentially subject us to significant concentrations of credit risk principally consist of cash, cash equivalents and marketable securities. We place our cash and cash equivalents and marketable securities with financial institutions with high credit ratings. As part of our cash and investment management processes, we perform periodic evaluations of the credit standing of the financial institutions with whom we maintain deposits, and have not recorded any credit losses to-date.</p> </div>
CY2016 us-gaap Depreciation
Depreciation
35792
CY2016 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2016 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18690960
CY2016 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2016 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2016 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3472
CY2016 us-gaap Interest Expense
InterestExpense
105509
CY2016 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000 pure
CY2016 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y1M10D
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.0263 pure
CY2016 us-gaap Interest Paid
InterestPaid
78128
CY2016 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
759822
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-18699450
CY2016 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-225234
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-575719
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-278870
CY2016 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
8490
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-18695978
CY2016 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
16048424
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
12738941
CY2016 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
8490
CY2016 us-gaap Investment Income Interest
InvestmentIncomeInterest
102037
CY2016 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
7400000
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2016 us-gaap Nature Of Operations
NatureOfOperations
<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td valign="top" width="4%" align="left"><b>1.</b></td> <td valign="top" align="left"><b>NATURE OF BUSINESS</b></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> Aldeyra Therapeutics, Inc. (the Company or Aldeyra) was incorporated in the state of Delaware on August&#xA0;13, 2004 as Neuron Systems, Inc. On December&#xA0;20, 2012, the Company changed its name to Aldexa Therapeutics, Inc. and, on March&#xA0;17, 2014, the Company changed its name to Aldeyra Therapeutics, Inc. The Company is a biotechnology company focused primarily on the development of new products for inflammation, inborn errors of metabolism and other diseases that are thought to be related to endogenously generated toxic and pro-inflammatory chemical species known as aldehydes. The ongoing research and development activities will be subject to extensive regulation by numerous governmental authorities in the United States. Prior to marketing in the United States, any drug developed by the Company must undergo rigorous preclinical and clinical testing and an extensive regulatory approval process implemented by the United States Food and Drug Administration (FDA) under the Food, Drug and Cosmetic Act. The Company has limited experience in conducting and managing the preclinical and clinical testing necessary to obtain regulatory approval. There can be no assurance that the Company will not encounter problems in the clinical trials that will cause the Company or the FDA to delay or suspend clinical trials.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> The Company&#x2019;s success will depend in part on its ability to obtain patents and product license rights, maintain trade secrets, and operate without infringing on the property rights of others, both in the United States and other countries. There can be no assurance that patents issued to or licensed by the Company will not be challenged, invalidated, circumvented, or that the rights granted thereunder will provide proprietary protection or competitive advantages to the Company.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> The Company&#x2019;s principal activities to date include raising capital and research and development activities.</p> </div>
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-15147512
CY2016 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 Segment
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
11810
CY2016 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
103804 shares
CY2016 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 0pt"> <b><i>Use of Estimates</i></b> &#x2013; The preparation of financial statements in conformity with US&#xA0;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company evaluates its estimates and assumptions on an ongoing basis. The most significant estimates in the Company&#x2019;s financial statements relate to accruals, including research and development costs, accounting for income taxes and the related valuation allowance and accounting for stock based compensation and the related fair value. Although these estimates are based on the Company&#x2019;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</p> </div>
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M10D
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent
SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
1.00 pure
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.43
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y1M6D
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.30
CY2016 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
10000000
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.88
CY2016 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
12613623
CY2016 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
89082
CY2016 dei Trading Symbol
TradingSymbol
ALDX
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13175670
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.89 pure
CY2016 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
240000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
759314 shares
CY2016 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
15835000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.43
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
171159 shares
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
2759753
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
11352230 shares
CY2016 aldx Net Operating Loss Carry Forwards Expiration Year
NetOperatingLossCarryForwardsExpirationYear
2036
CY2016 aldx Deferred Tax Assets Tax Credit Carryforwards Research Expiration Year
DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear
2036
CY2016 aldx Deferred Tax Assets Valuation Allowance Percentage
DeferredTaxAssetsValuationAllowancePercentage
1.00 pure
CY2016 aldx Initial Public Offering Date Of Completion
InitialPublicOfferingDateOfCompletion
2014-05-07
CY2016 aldx Investment Maturity Period
InvestmentMaturityPeriod
Three months or less
CY2016 aldx Number Of Incentive Plans
NumberOfIncentivePlans
3 Incentive_Plan
CY2016 aldx Payment Of Underwriting Discounts And Commissions
PaymentOfUnderwritingDiscountsAndCommissions
800000
CY2016 aldx Proceeds From Issuance Of Common Stock And Options Exercised
ProceedsFromIssuanceOfCommonStockAndOptionsExercised
12738941
CY2016 aldx Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice
4.85
CY2016 aldx Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod
63096 shares
CY2016 aldx Prepaid Offering And Printing Costs
PrepaidOfferingAndPrintingCosts
1000000
CY2016 aldx Investment Securities Maturity Period
InvestmentSecuritiesMaturityPeriod
P90D

Files In Submission

Name View Source Status
0001193125-17-104228-index-headers.html Edgar Link pending
0001193125-17-104228-index.html Edgar Link pending
0001193125-17-104228.txt Edgar Link pending
0001193125-17-104228-xbrl.zip Edgar Link pending
aldx-20161231.xml Edgar Link completed
aldx-20161231.xsd Edgar Link pending
aldx-20161231_cal.xml Edgar Link unprocessable
aldx-20161231_def.xml Edgar Link unprocessable
aldx-20161231_lab.xml Edgar Link unprocessable
aldx-20161231_pre.xml Edgar Link unprocessable
d318309d10k.htm Edgar Link pending
d318309dex1021.htm Edgar Link pending
d318309dex1025.htm Edgar Link pending
d318309dex231.htm Edgar Link pending
d318309dex311.htm Edgar Link pending
d318309dex312.htm Edgar Link pending
d318309dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g318309g48f88.jpg Edgar Link pending
g318309g54w48.jpg Edgar Link pending
g318309g62k37.jpg Edgar Link pending
g318309g64s46.jpg Edgar Link pending
g318309g97r19.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending